Is CJC-1295 Ipamorelin Safe? What We Know

Is CJC-1295 ipamorelin safe? We don't have enough long-term human evidence to give it a clean yes. Each peptide has been studied separately, mostly in short trials, and no published trial has tested the blend itself. The available studies offer limited short-term reassurance, but they leave the risks of months or years of treatment unsettled.

That isn't the same as saying every prescription is unsafe. It means the answer depends heavily on medical history, the exact form in the vial, pharmacy quality and clinical follow-up. The separate question of whether CJC-1295 with ipamorelin works has the same central evidence gap.

Is CJC-1295 ipamorelin safe in human trials?

There is no human safety trial of the two-peptide blend. CJC-1295 is a growth-hormone-releasing hormone analogue, meaning it copies a signal that asks the pituitary gland to release growth hormone. Ipamorelin is a growth-hormone secretagogue, a compound that prompts the same gland through the ghrelin receptor. They take different routes into the same hormone system.

In the best-known CJC-1295 study, healthy adults ages 21 to 61 received one or several injections of the long-acting DAC form. DAC is a chemical attachment that keeps the peptide in the blood for days. Mean growth hormone rose two- to tenfold for at least six days, and IGF-1 rose 1.5- to threefold for 9 to 11 days. The researchers reported no serious adverse reactions, but this was a small hormone-and-drug-exposure study, not long-term safety research (Teichman et al., The Journal of Clinical Endocrinology & Metabolism, 2006).

Ipamorelin's largest published trial looked nothing like routine outpatient use. It enrolled 117 people having bowel surgery; 114 were included in the safety analysis. They received intravenous ipamorelin or placebo for up to seven days. Adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, and investigators called it well tolerated. Those high rates came from patients recovering from surgery, so they cannot predict months of subcutaneous use (Beck et al., International Journal of Colorectal Disease, 2014).

The serious CJC-1295 event should not be skipped

A separate, unpublished phase 2 CJC-1295 study enrolled 192 people with HIV-associated body-fat changes. According to the FDA's detailed CJC-1295 review, one participant developed chest discomfort and a confirmed heart attack about two hours after the 11th weekly dose, then died about an hour later. The trial was stopped.

The treating physician attributed the death to previously silent coronary artery disease with plaque rupture and blockage, rather than to CJC-1295. That means the report does not establish that the peptide caused the death. It also cannot provide much reassurance: the trial results were never published, and FDA said it had no further information about events in the other participants.

What the long-term concerns actually mean

The unanswered questions mostly come from the pathway these peptides activate. IGF-1, or insulin-like growth factor 1, is a downstream growth signal. Because CJC-1295 raised both growth hormone and IGF-1 in the short study, clinicians have to think about effects known from growth-hormone medicine while remembering that this blend is not growth hormone and has not been studied the same way.

In adults treated with growth hormone for a diagnosed deficiency, known dose-related effects include fluid retention and reduced insulin sensitivity, meaning the body has more trouble moving glucose out of the blood (Jørgensen and Juul, European Journal of Endocrinology, 2018). That is indirect evidence, not a measured rate for CJC-1295 or ipamorelin. It explains why swelling and glucose changes deserve attention rather than proving they will happen. The fuller symptom discussion belongs in ipamorelin side effects.

Cancer risk needs the same restraint. Higher blood IGF-1 has been associated with a slightly greater risk of some cancers, but association does not prove that raising IGF-1 caused them (Clayton et al., Nature Reviews Endocrinology, 2011). A 2022 consensus review of growth-hormone replacement in cancer survivors found no association with a first tumor returning, while still calling for individual risk review (Boguszewski et al., European Journal of Endocrinology, 2022). Neither paper tested this blend. So it would be wrong to say CJC-1295/ipamorelin causes cancer, and just as wrong to call it proven safe for someone with a cancer history.

What changed in 2026

As of September 9, 2026, the day this article was written, three current primary sources sharpened the practical answer. An August 11 scoping review covering six performance peptides, including CJC-1295 and ipamorelin, found that 67% of the publications it identified used animal models. Human studies were only a handful, and most lacked strong controls (Tewari et al., The American Journal of Sports Medicine, 2026). It was not a safety trial of the blend, but it confirms how little human evidence sits behind broad claims.

On September 4, Argentina's medicines regulator ANMAT warned about unknown-origin injectable peptides sold through online platforms and named Ipamorelin/CJC-1295. ANMAT said the manufacturer, composition and production conditions of those products were unknown. Its alert concerned unauthorized products in Argentina, not patient-specific prescriptions dispensed by licensed U.S. pharmacies. The useful lesson is narrower: the source of an injectable is part of its safety.

The FDA's 503A list for traditional compounding pharmacies was updated May 14. It lists neither CJC-1295 nor ipamorelin in Categories 1, 2 or 3. On FDA's separate safety page, CJC-1295 appears under "nominated but withdrawn." Ipamorelin acetate appears in the active Category 2 table for 503B outsourcing facilities and in the withdrawn table for 503A. Category 2 means FDA identified potential significant safety risks under an interim policy; withdrawn means the nominator withdrew the request, not that FDA declared the substance safe.

No FDA-approved product exists for either CJC-1295 or ipamorelin, and the compounded formulation offered here is not FDA-approved. That status is one input into care, not a marketing verdict. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

What a careful prescription route changes

A prescription does not erase the unknowns. It changes who is accountable for them. The record identifies the clinician, the dispensing pharmacy, the formulation and the lot. It also creates a route for reporting a reaction and deciding whether treatment should change. An anonymous vial sold without a prescription offers none of that.

Form matters too. The human CJC-1295 results came from the long-acting DAC molecule, while many blends use a short-acting form. CJC-1295 without DAC explains why findings cannot simply move from one form to the other. A provider may consider cancer history, heart disease, glucose problems, pituitary conditions, pregnancy, current medicines and any baseline labs before deciding whether the uncertainty is acceptable.

At Promise, a licensed provider reviews every request and not everyone qualifies. If the CJC-1295 / Ipamorelin prescription is written, follow-up gives the provider a chance to compare symptoms and relevant labs with the starting point. That is the safest honest frame available here: limited evidence, a real medical gate and someone responsible for what happens next.